Sana Biotechnology's (SANA) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• Analysts at Weiss Ratings have reaffirmed a "sell (e+)" rating for Sana Biotechnology (NASDAQ:SANA), indicating ongoing concerns about the company's financial performance.
• Despite Weiss Ratings' stance, other firms such as JMP Securities and Morgan Stanley have issued higher target prices of $5.00 and $12.00 respectively, with seven analysts rating the stock as a Buy.
• Sana Biotechnology's stock recently experienced a 10% increase, opening at $4.53, and boasts a market capitalization of approximately $1.08 billion.

Sana Biotechnology (NASDAQ:SANA - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other analysts also recently issued research reports about the stock. JMP Securities reiterated a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley started coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price for the company. Finally, Wedbush started coverage on shares of Sana Biotechnology in a report on Wednesday, September 24th. They issued an "outperform" rating and a $5.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Sana Biotechnology Trading Up 10.0%

Sana Biotechnology stock opened at $4.53 on Wednesday. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.30. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -4.27 and a beta of 1.91. The firm's fifty day moving average price is $3.41 and its two-hundred day moving average price is $2.83.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. On average, research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Trading of Sana Biotechnology

A number of large investors have recently added to or reduced their stakes in the stock. Viewpoint Capital Management LLC increased its holdings in Sana Biotechnology by 19.1% during the second quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company's stock worth $77,000 after buying an additional 4,500 shares during the last quarter. Captrust Financial Advisors boosted its position in Sana Biotechnology by 43.8% during the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company's stock worth $43,000 after purchasing an additional 4,807 shares during the period. BNP Paribas Financial Markets boosted its position in Sana Biotechnology by 46.9% during the second quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company's stock worth $42,000 after purchasing an additional 4,931 shares during the period. Summit X LLC boosted its position in Sana Biotechnology by 18.5% during the second quarter. Summit X LLC now owns 42,665 shares of the company's stock worth $116,000 after purchasing an additional 6,665 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Sana Biotechnology by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company's stock worth $578,000 after purchasing an additional 7,230 shares during the period. Hedge funds and other institutional investors own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.